Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus

BMC Musculoskeletal Disorders

Thomas Brune¹  Jörn Kekow³  Sibylle Jakubiczka²  Susanne Drynda³  Maria Barleben¹  Marianne Kekow¹ 

[1] Children's Hospital, University of Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany;Institute of Human Genetics, University of Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany;Clinic of Rheumatology, University of Magdeburg, Sophie-von-Boetticher-Strasse 1, Vogelsang, Gommern 39245, Germany

关键词: Pregnancy;    SLE;    RA;    Microchimerism;   

Others  :  1129162
DOI  :  10.1186/1471-2474-14-325

 received in 2013-07-10, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Background

The discovery of a fetal cells transfer to the mother is a phenomenon with multiple implications for autoimmunity and tolerance. The prevalence and meaning of the feto-maternal microchimerism (MC) in rheumatic diseases has not been thoroughly investigated. The aim of this study was to analyze the prevalence of fetal MC in patients with inflammatory rheumatic diseases and to investigate the association of MC with disease onset and current status.

Methods

A total of 142 women who gave birth to at least one male offspring were recruited: 72 women with rheumatoid arthritis (RA), 16 women with systemic lupus erythematosus (SLE), and 54 healthy women. For the detection of fetal microchimerism a nested PCR method was used to amplify a Y chromosome specific sequence (TSPY1). For characterization of disease activity we analyzed autoantibody profiles and X-rays in RA, and in addition complement levels in SLE respectively.

Results

A significant higher prevalence of fetal MC was found in RA (18%) and SLE (31%) compared to controls (3.7%) (p = 0.02 and p = 0.006, resp.). The mean age at disease onset was comparable in MC + and MC- RA patients. Disease onset occurred 18.7 (MC +) and 19.8 (MC-) years post partum of the first son, respectively. The presence of anti-CCP and RF did not differ significantly, anti-CCP were found in 75% of MC + and 87% of MC- patients, RF in 75% of both MC + and MC- patients. A slightly higher mean Steinbrocker score in MC + patients was associated with longer disease duration in MC + compared to MC- RA. In SLE patients the mean age at disease onset was 42.6 years in MC + and 49.1 years in MC- patients. Disease onset occurred 24.0 and 26.4 years post partum of the first son for MC + and MC- patients, respectively. The presence of ANA and anti-dsDNA antibodies, C3, C4 and CH50 did not differ significantly.

Conclusion

Our results indicate a higher frequency of long-term male MC in RA and SLE patients compared with controls without impact on disease onset and status in RA and SLE.

【 授权许可】

   
2013 Kekow et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Firestein G, Budd C, Harris E, McInnes I, Ruddy S, Sergent J: Kelly's textbook of rheumatology Vol.II. 8th edition. Philadelphia PA: Saunders Elsevier; 2008.
• [2]Guthrie KA, Dugowson CE, Voigt LF, Koepsell TD, Nelson JL: Does pregnancy provide vaccine-like protection against rheumatoid arthritis? Arthritis Rheum 2010, 62:1842-1848.
• [3]Bianchi DW: Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta 2004, 25 Suppl A:S93-S101.
• [4]Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
• [5]Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL: Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999, 93:2033-2037.
• [6]Lambert N, Nelson JL: Microchimerism in autoimmune disease: more questions than answers? Autoimmun Rev 2003, 2:133-139.
• [7]Fan HC, Gu W, Wang J, Blumenfeld YJ, El-Sayed YY, Quake SR: Non-invasive prenatal measurement of the fetal genome. Nature 2012, 487:320-324.
• [8]Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE, Gammill HS, Rubens CE, Santillan DA, Murray JC, Tabor HK, Bamshad MJ, Eichler EE, Shendure J: Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 2012, 4:1-18. 137ra76
• [9]Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA: Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993, 329:466-471.
• [10]Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW: Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998, 351:559-562.
• [11]Artlett CM, Welsh KI, Black CM, Jimenez SA: Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenetics 1997, 47:17-22.
• [12]Artlett CM, Smith JB, Jimenez SA: Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998, 338:1186-1191.
• [13]Hamada H, Arinami T, Hamaguchi H, Kubo T: Fetal nucleated cells in maternal peripheral blood after delivery. Am J Obstet Gynecol 1994, 170:1188-1193.
• [14]Rak JM, Maestroni L, Balandraud N, Guis S, Boudinet H, Guzian MC, Yan Z, Azzouz D, Auger I, Roudier C, Martin M, Didelot R, Roudier J, Lambert NC: Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis. Arthritis Rheum 2009, 60:73-80.
• [15]Miyashita Y, Ono M, Ono M, Ueki H, Kurasawa K: Y chromosome microchimerism in rheumatic autoimmune disease. Ann Rheum Dis 2000, 59:655-656.
• [16]Toda I, Kuwana M, Tsubota K, Kawakami Y: Lack of evidence for an increased microchimerism in the circulation of patients with Sjogren's syndrome. Ann Rheum Dis 2001, 60:248-253.
• [17]Barleben M: Kinetik des Auftretens fetaler DNA im mütterlichen Blut während und nach der Schwangerschaft. Germany: PhD thesis University of Magdeburg, Medical faculty; 2012.
• [18]Bonney EA, Matzinger P: The maternal immune system's interaction with circulating fetal cells. J Immunol 1997, 158:40-47.
• [19]Hamada H, Arinami T, Kubo T, Hamaguchi H, Iwasaki H: Fetal nucleated cells in maternal peripheral blood: frequency and relationship to gestational age. Hum Genet 1993, 91:427-432.
• [20]Nguyen Huu S, Dubernard G, Aractingi S, Khosrotehrani K: Feto-maternal cell trafficking: a transfer of pregnancy associated progenitor cells. Stem Cell Rev 2006, 2:111-116.
• [21]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [22]Petri M: Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 2005, 31:245-254.
• [23]Pincus T, Larsen A, Brooks RH, Kaye J, Nance EP, Callahan LF: Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker stage, Kaye modified Sharp score, and Larsen score. J Rheumatol 1997, 24:2106-2112.
• [24]Kaye JJ, Fuchs HA, Moseley JW, Nance EP Jr, Callahan LF, Pincus T: Problems with the Steinbrocker staging system for radiographic assessment of the rheumatoid hand and wrist. Invest Radiol 1990, 25:536-544.
• [25]Arnemann J, Epplen JT, Cooke HJ, Sauermann U, Engel W, Schmidtke J: A human Y-chromosomal DNA sequence expressed in testicular tissue. Nucleic Acids Res 1987, 15:8713-8724.
• [26]Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, Nagel D, Lo YM: Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 2005, 51:1544-1546.
• [27]Zimmermann B, El-Sheikhah A, Nicolaides K, Holzgreve W, Hahn S: Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem 2005, 51:1598-1604.
• [28]Lo YM, Lau TK, Chan LY, Leung TN, Chang AM: Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin Chem 2000, 46:1301-1309.
• [29]Yan Z, Aydelotte T, Gadi VK, Guthrie KA, Nelson JL: Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism. Arthritis Rheum 2011, 63:640-644.
• [30]Yan Z, Lambert NC, Ostensen M, Adams KM, Guthrie KA, Nelson JL: Prospective study of fetal DNA in serum and disease activity during pregnancy in women with inflammatory arthritis. Arthritis Rheum 2006, 54:2069-2073.
• [31]Yan Z, Lambert NC, Guthrie KA, Porter AJ, Loubiere LS, Madeleine MM, Stevens AM, Hermes HM, Nelson JL: Male microchimerism in women without sons: quantitative assessment and correlation with pregnancy history. Am J Med 2005, 118:899-906.
• [32]Atkins CJ, Chan WFN, Naismith D, van der Westhuizen N, Woo J, Cortez V: The Clinical Features of 13 Women with Microchimerism in Rheumatoid Nodules. Arthritis Rheum 2010, 62(Suppl 10):1060.
• [33]Johnson KL, McAlindon TE, Mulcahy E, Bianchi DW: Microchimerism in a female patient with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2107-2111.
• [34]Hromadnikova I, Zlacka D, Hien Nguyen TT, Sedlackova L, Zejskova L, Sosna A: Fetal cells of mesenchymal origin in cultures derived from synovial tissue and skin of patients with rheumatoid arthritis. Joint Bone Spine 2008, 75:563-566.
• [35]Mosca M, Curcio M, Lapi S, Valentini G, D'Angelo S, Rizzo G, Bombardieri S: Correlations of Y chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data. Ann Rheum Dis 2003, 62:651-654.
• [36]Kremer Hovinga IC, Koopmans M, Baelde HJ, de Heer E, Bruijn JA, Bajema IM: Tissue chimerism in systemic lupus erythematosus is related to injury. Ann Rheum Dis 2007, 66:1568-1573.
• [37]Kremer Hovinga IC, Koopmans M, Baelde HJ, van der Wal AM, Sijpkens YW, de Heer E, Bruijn JA, Bajema IM: Chimerism occurs twice as often in lupus nephritis as in normal kidneys. Arthritis Rheum 2006, 54:2944-2950.
• [38]Khosrotehrani K, Johnson KL, Lau J, Dupuy A, Cha DH, Bianchi DW: The influence of fetal loss on the presence of fetal cell microchimerism: a systematic review. Arthritis Rheum 2003, 48:3237-3241.
• [39]Petz LD: Bone Marrow Transplantation. In Clinical practice of transfusion medicine. 3rd edition. Edited by Petz LD, Swisher SN, Kleinman SN, Spencer RP, Strauss RG. New York: Churchill-Livingstone; 1996:772-776.
• [40]Kremer Hovinga IC, Koopmans M, de Heer E, Bruijn JA, Bajema IM: Chimerism in systemic lupus erythematosus–three hypotheses. Rheumatology (Oxford) 2007, 46:200-208.